Biothera Appoints CEO
This article was originally published in Scrip
Biothera Pharmaceutical Inc. has appointed Barry Labinger CEO – effective Dec. 14, 2015. With nearly 30 years' experience, Labinger joins the company having most recently served as executive vice president (VP) and president, biosciences division at Emergent BioSolutions, Inc. Previously he was executive VP and chief commercial officer of Human Genome Sciences, Inc. and prior to this he was division VP of 3M Pharmaceuticals. Prior to 3M, he was senior VP and general manager of commercial operations for Immunex Corporation.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.